human milteny biotech (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
93
Structured Review
Miltenyi Biotec
human milteny biotech
Human Milteny Biotech, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd127/CD127+MicroBead+Kit%2C+human/pm42379172-272-100-101
Average 93 stars, based on 13 article reviews
Human Milteny Biotech, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd127/CD127+MicroBead+Kit%2C+human/pm42379172-272-100-101
Average 93 stars, based on 13 article reviews
human milteny biotech - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
Control:Article Title: CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma. Article Snippet: To control for unspecific background staining an FMO control was used (gray histogram). (B) Surface expression levels of exhaustion markers PD-1 (Miltenyi, Cat#130-120-385), LAG-3 (Miltenyi, Cat#130-118-549), and TIM-3 (Miltenyi, Cat#130-119-781) on PB CD4+ (upper row) and CD8+ (lower row) CAR T cells from our patient on day+7 and day+14 post CAR-T treatment, respectively. .. To control for unspecific background staining an FMO control was used (gray histogram). (C) Surface expression levels of Staining:Article Title: CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma. Article Snippet: To control for unspecific background staining an FMO control was used (gray histogram). (B) Surface expression levels of exhaustion markers PD-1 (Miltenyi, Cat#130-120-385), LAG-3 (Miltenyi, Cat#130-118-549), and TIM-3 (Miltenyi, Cat#130-119-781) on PB CD4+ (upper row) and CD8+ (lower row) CAR T cells from our patient on day+7 and day+14 post CAR-T treatment, respectively. .. To control for unspecific background staining an FMO control was used (gray histogram). (C) Surface expression levels of Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease. Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), Article Title: T cell immune response to influenza vaccination when administered prior to and following autologous CAR-T cell therapy. Article Snippet: Background: Chimeric antigen receptor-modified T (CAR-T) cell therapies are gaining wider use in relapsed and refractory malignancies.. However, data on vaccination in this population is lacking.. We evaluated T cell responses in an established cohort of CAR-T recipients and healthy controls before and after 2019-2020 influenza vaccination. Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), Article Title: Epigenetic control of multiple genes with a lentiviral vector encoding transcriptional repressors fused to compact zinc finger arrays Article Snippet: For cellular immunophenotyping, T cells were stained with conjugated monoclonal antibodies (mAb) targeting CD3, CD4, CD8, CD5, and CD271/NGFR (Miltenyi Biotec) MHC-I and MHC-II (BD Biosciences, Le Pont de Claix, France). .. For HLA-A2 CAR-Treg labeling, cells were stained at cell surface with conjugated mAb targeting CD4, CD25, and Expressing:Article Title: CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma. Article Snippet: To control for unspecific background staining an FMO control was used (gray histogram). (B) Surface expression levels of exhaustion markers PD-1 (Miltenyi, Cat#130-120-385), LAG-3 (Miltenyi, Cat#130-118-549), and TIM-3 (Miltenyi, Cat#130-119-781) on PB CD4+ (upper row) and CD8+ (lower row) CAR T cells from our patient on day+7 and day+14 post CAR-T treatment, respectively. .. To control for unspecific background staining an FMO control was used (gray histogram). (C) Surface expression levels of Labeling:Article Title: Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus Article Snippet: Immunohistochemical analysis was performed on selected sections of spleen using rabbit anti-human CD3 (2GV6; Ventana) and mouse anti-human CD20 (L26; Ventana) in automated Ventana Discovery ULTRA system. .. For Treg phenotype, cells were labeled with titrated fluorescent monoclonal antibodies specific for CD3 (eFluor506, Invitrogen, OKT3, 69-0037-42, 1:75), CD4 (PE-Vio615, Miltenyi, REA623, 130-113-226, 1:150), FoxP3 (PE-Cy5, eBioscience, PCH101, 15-4776-42, 1:1500), CD45RA (BUV496, BD Bioscience, 5H9, 741182, 1:150), CD62L (BUV737, BD Bioscience, SK11, 749210, 1:300), TIGIT (BV786, BD Bioscience, 741182, 747838, 1:100), LAP (Per-CP-eFluor710, eBioscience, FNLAP, 46-9829-42, 1:100), Helios (PE, Biolegend, 22F6, 137216, 1:75), CD25 (PE-Vio770, Miltenyi, REA945, 130-116-205, 1:75), CD27 (APC, Biolegend, M-T271, 356410, 1:150), CD137 (Alexa Fluor 700, Biolegend, 4B4-1, 309816, 1:150), Article Title: Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus Article Snippet: Human T cells were counted on peripheral blood using Flow Count fluorescent beads (Beckman Coulter), according to manufacturer’s instruction. .. For Treg analysis in harvested organs, single-cell suspensions were labeled with fluorochrome-conjugated monoclonal antibodies specific for CD3 (eFluor506, Invitrogen, OKT3, 69-0037-42, 1:75), CD4 (PE-Vio615, Miltenyi, REA623, 130-113-226, 1:150), FoxP3 (PE-Cy5, eBioscience, PCH101, 15-4776-42, 1:1500), CD45RA (BUV496, BD Bioscience, 5H9, 741182, 1:150), CD62L (BUV737, BD Bioscience, SK11, 749210, 1:300), TIGIT (BV786, BD Bioscience, 741182, 747838, 1:100), LAP (Per-CP-eFluor710, eBioscience, FNLAP, 46-9829-42, 1:100), Helios (PE, Biolegend, 22F6, 137216, 1:75), CD25 (PE-Vio770, Miltenyi, REA945, 130-116-205, 1:75), CD27 (APC, Biolegend, M-T271, 356410, 1:150), CD137 (Alexa Fluor 700, Biolegend, 4B4-1, 309816, 1:150), Article Title: Epigenetic control of multiple genes with a lentiviral vector encoding transcriptional repressors fused to compact zinc finger arrays Article Snippet: For cellular immunophenotyping, T cells were stained with conjugated monoclonal antibodies (mAb) targeting CD3, CD4, CD8, CD5, and CD271/NGFR (Miltenyi Biotec) MHC-I and MHC-II (BD Biosciences, Le Pont de Claix, France). .. For HLA-A2 CAR-Treg labeling, cells were stained at cell surface with conjugated mAb targeting CD4, CD25, and Bioprocessing:Article Title: Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus Article Snippet: Immunohistochemical analysis was performed on selected sections of spleen using rabbit anti-human CD3 (2GV6; Ventana) and mouse anti-human CD20 (L26; Ventana) in automated Ventana Discovery ULTRA system. .. For Treg phenotype, cells were labeled with titrated fluorescent monoclonal antibodies specific for CD3 (eFluor506, Invitrogen, OKT3, 69-0037-42, 1:75), CD4 (PE-Vio615, Miltenyi, REA623, 130-113-226, 1:150), FoxP3 (PE-Cy5, eBioscience, PCH101, 15-4776-42, 1:1500), CD45RA (BUV496, BD Bioscience, 5H9, 741182, 1:150), CD62L (BUV737, BD Bioscience, SK11, 749210, 1:300), TIGIT (BV786, BD Bioscience, 741182, 747838, 1:100), LAP (Per-CP-eFluor710, eBioscience, FNLAP, 46-9829-42, 1:100), Helios (PE, Biolegend, 22F6, 137216, 1:75), CD25 (PE-Vio770, Miltenyi, REA945, 130-116-205, 1:75), CD27 (APC, Biolegend, M-T271, 356410, 1:150), CD137 (Alexa Fluor 700, Biolegend, 4B4-1, 309816, 1:150), Article Title: Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus Article Snippet: Human T cells were counted on peripheral blood using Flow Count fluorescent beads (Beckman Coulter), according to manufacturer’s instruction. .. For Treg analysis in harvested organs, single-cell suspensions were labeled with fluorochrome-conjugated monoclonal antibodies specific for CD3 (eFluor506, Invitrogen, OKT3, 69-0037-42, 1:75), CD4 (PE-Vio615, Miltenyi, REA623, 130-113-226, 1:150), FoxP3 (PE-Cy5, eBioscience, PCH101, 15-4776-42, 1:1500), CD45RA (BUV496, BD Bioscience, 5H9, 741182, 1:150), CD62L (BUV737, BD Bioscience, SK11, 749210, 1:300), TIGIT (BV786, BD Bioscience, 741182, 747838, 1:100), LAP (Per-CP-eFluor710, eBioscience, FNLAP, 46-9829-42, 1:100), Helios (PE, Biolegend, 22F6, 137216, 1:75), CD25 (PE-Vio770, Miltenyi, REA945, 130-116-205, 1:75), CD27 (APC, Biolegend, M-T271, 356410, 1:150), CD137 (Alexa Fluor 700, Biolegend, 4B4-1, 309816, 1:150), Single Cell:Article Title: Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus Article Snippet: Human T cells were counted on peripheral blood using Flow Count fluorescent beads (Beckman Coulter), according to manufacturer’s instruction. .. For Treg analysis in harvested organs, single-cell suspensions were labeled with fluorochrome-conjugated monoclonal antibodies specific for CD3 (eFluor506, Invitrogen, OKT3, 69-0037-42, 1:75), CD4 (PE-Vio615, Miltenyi, REA623, 130-113-226, 1:150), FoxP3 (PE-Cy5, eBioscience, PCH101, 15-4776-42, 1:1500), CD45RA (BUV496, BD Bioscience, 5H9, 741182, 1:150), CD62L (BUV737, BD Bioscience, SK11, 749210, 1:300), TIGIT (BV786, BD Bioscience, 741182, 747838, 1:100), LAP (Per-CP-eFluor710, eBioscience, FNLAP, 46-9829-42, 1:100), Helios (PE, Biolegend, 22F6, 137216, 1:75), CD25 (PE-Vio770, Miltenyi, REA945, 130-116-205, 1:75), CD27 (APC, Biolegend, M-T271, 356410, 1:150), CD137 (Alexa Fluor 700, Biolegend, 4B4-1, 309816, 1:150), Isolation:Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease. Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), FACS:Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease. Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), Article Title: Early-life thymectomy leads to an increase of granzyme-producing γδ T cells in children with congenital heart disease Article Snippet: .. For isolation of described populations on an FACS AriaTM Fusion (BD), thawed PBMCs were stained with antibodies directed against the following surface antibodies: CD3 (PE-Cy7, SK7, BD, 1:50), TCRγδ (PE, REA591, Miltenyi, 1:50), TCRαβ (FITC, WT31, BD, 1:50), CD4 (PerCP, M-T466, Miltenyi, 1:50), CD8 (APC-Cy7, SK1, BioLegend, 1:20), CD25 (BV605, BC96, BioLegend, 1:50), Incubation:Article Title: Epigenetic control of multiple genes with a lentiviral vector encoding transcriptional repressors fused to compact zinc finger arrays Article Snippet: For cellular immunophenotyping, T cells were stained with conjugated monoclonal antibodies (mAb) targeting CD3, CD4, CD8, CD5, and CD271/NGFR (Miltenyi Biotec) MHC-I and MHC-II (BD Biosciences, Le Pont de Claix, France). .. For HLA-A2 CAR-Treg labeling, cells were stained at cell surface with conjugated mAb targeting CD4, CD25, and |
![In vivo efficacy and biodistribution of IL-7Rα-targeting agents. (a) Schematic representation of the subcutaneous tumor model and treatment schedule with four IL-7Rα-targeting ADCs. (b) Tumor volumes over time for each treatment group. (c) Relative body weight changes during treatment. PBS, phosphate-buffered saline. Lines show mean ± SEM, n = 6–9 per group. (d) Serial in vivo fluorescence imaging of fluorophore-labelled parent anti-IL-7Rα mAbs and an isotype antibody control in a separate tracer-dose cohort (representative animals). (e) Quantification of tumor region-of-interest (ROI) fluorescence; each animal was normalized to its own 5-min post-injection value. NC, negative control. Data are presented as mean ± SEM; n = 3–5 per group. (f) Relative performance of the four anti-IL-7Rα mAbs (577, 2D5, 165, and 24) was compared across five parameters. Binding activity, SPR-derived apparent binding affinity, internalization, and pIC 50 (-log10 IC 50 [M]) and in vivo efficacy were evaluated using the respective ADCs. Ratings were assigned based on the experimental data shown in , using a semi-quantitative scale from “+” (lowest) to “++++” (highest). The scale reflects the relative ranking within each parameter and does not represent absolute quantitative values.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8026/pmc13128026/pmc13128026__KMAB_A_2663639_F0003_OC.jpg)
